Hua Medicine (Shanghai) Ltd. (2552.HK)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Li Chen Ph.D. | Founder, CEO & Executive Director | 10.51M | -- | 1964 |
| Dr. Yi Zhang M.D., Ph.D. | Senior VP of Pharma Development, Chief Medical Officer China and Executive Director | 4.51M | -- | 1976 |
| Mr. Chien Cheng Lin J.D. | Executive VP & Chief Strategy Officer | 5.9M | -- | 1971 |
| Dr. Fuxing Tang Ph.D. | CTO, VP of Chemical Manufacturing Control Department and Head of R&D in USA | -- | -- | 1967 |
| Dr. Changhong Li Ph.D. | Chief Scientific Officer | -- | -- | 1969 |
| Mr. Chengde Wang | Head of IR | -- | -- | 1948 |
| Mr. Yu Lu | Vice President of Sales & Marketing | -- | -- | -- |
| Mr. Ying Xie M.B.A. | VP of Quality Assurance Division & Chief Quality Officer | -- | -- | -- |
| Ms. Wing Yan Yuen FCIS, FCS | Company Secretary | -- | -- | 1970 |
Hua Medicine (Shanghai) Ltd.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 168
Description
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is based in Shanghai, China.
Corporate Governance
Upcoming Events
March 27, 2025 at 10:59 AM UTC
Hua Medicine (Shanghai) Ltd. Earnings Date
Recent Events
Recent Events Information Not Available